BACKGROUND: Mobile stroke units (MSUs) are ambulances with staff and a computed tomographic scanner that may enable faster treatment with tissue plasminogen activator (t-PA) than standard management by emergency medical services (EMS). Whether and how much MSUs alter outcomes has not been extensively studied. METHODS: In an observational, prospective, multicenter, alternating-week trial, we assessed outcomes from MSU or EMS management within 4.5 hours after onset of acute stroke symptoms. The primary outcome was the score on the utility-weighted modified Rankin scale (range, 0 to 1, with higher scores indicating better outcomes according to a patient value system, derived from scores on the modified Rankin scale of 0 to 6, with higher scores indicating more disability). The main analysis involved dichotomized scores on the utility-weighted modified Rankin scale (≥0.91 or <0.91, approximating scores on the modified Rankin scale of ≤1 or >1) at 90 days in patients eligible for t-PA. Analyses were also performed in all enrolled patients. RESULTS: We enrolled 1515 patients, of whom 1047 were eligible to receive t-PA; 617 received care by MSU and 430 by EMS. The median time from onset of stroke to administration of t-PA was 72 minutes in the MSU group and 108 minutes in the EMS group. Of patients eligible for t-PA, 97.1% in the MSU group received t-PA, as compared with 79.5% in the EMS group. The mean score on the utility-weighted modified Rankin scale at 90 days in patients eligible for t-PA was 0.72 in the MSU group and 0.66 in the EMS group (adjusted odds ratio for a score of ≥0.91, 2.43; 95% confidence interval [CI], 1.75 to 3.36; P<0.001). Among the patients eligible for t-PA, 55.0% in the MSU group and 44.4% in the EMS group had a score of 0 or 1 on the modified Rankin scale at 90 days. Among all enrolled patients, the mean score on the utility-weighted modified Rankin scale at discharge was 0.57 in the MSU group and 0.51 in the EMS group (adjusted odds ratio for a score of ≥0.91, 1.82; 95% CI, 1.39 to 2.37; P<0.001). Secondary clinical outcomes generally favored MSUs. Mortality at 90 days was 8.9% in the MSU group and 11.9% in the EMS group. CONCLUSIONS: In patients with acute stroke who were eligible for t-PA, utility-weighted disability outcomes at 90 days were better with MSUs than with EMS. (Funded by the Patient-Centered Outcomes Research Institute; BEST-MSU ClinicalTrials.gov number, NCT02190500.).
BACKGROUND: Mobile stroke units (MSUs) are ambulances with staff and a computed tomographic scanner that may enable faster treatment with tissue plasminogen activator (t-PA) than standard management by emergency medical services (EMS). Whether and how much MSUs alter outcomes has not been extensively studied. METHODS: In an observational, prospective, multicenter, alternating-week trial, we assessed outcomes from MSU or EMS management within 4.5 hours after onset of acute stroke symptoms. The primary outcome was the score on the utility-weighted modified Rankin scale (range, 0 to 1, with higher scores indicating better outcomes according to a patient value system, derived from scores on the modified Rankin scale of 0 to 6, with higher scores indicating more disability). The main analysis involved dichotomized scores on the utility-weighted modified Rankin scale (≥0.91 or <0.91, approximating scores on the modified Rankin scale of ≤1 or >1) at 90 days in patients eligible for t-PA. Analyses were also performed in all enrolled patients. RESULTS: We enrolled 1515 patients, of whom 1047 were eligible to receive t-PA; 617 received care by MSU and 430 by EMS. The median time from onset of stroke to administration of t-PA was 72 minutes in the MSU group and 108 minutes in the EMS group. Of patients eligible for t-PA, 97.1% in the MSU group received t-PA, as compared with 79.5% in the EMS group. The mean score on the utility-weighted modified Rankin scale at 90 days in patients eligible for t-PA was 0.72 in the MSU group and 0.66 in the EMS group (adjusted odds ratio for a score of ≥0.91, 2.43; 95% confidence interval [CI], 1.75 to 3.36; P<0.001). Among the patients eligible for t-PA, 55.0% in the MSU group and 44.4% in the EMS group had a score of 0 or 1 on the modified Rankin scale at 90 days. Among all enrolled patients, the mean score on the utility-weighted modified Rankin scale at discharge was 0.57 in the MSU group and 0.51 in the EMS group (adjusted odds ratio for a score of ≥0.91, 1.82; 95% CI, 1.39 to 2.37; P<0.001). Secondary clinical outcomes generally favored MSUs. Mortality at 90 days was 8.9% in the MSU group and 11.9% in the EMS group. CONCLUSIONS: In patients with acute stroke who were eligible for t-PA, utility-weighted disability outcomes at 90 days were better with MSUs than with EMS. (Funded by the Patient-Centered Outcomes Research Institute; BEST-MSU ClinicalTrials.gov number, NCT02190500.).
Authors: Praveen Hariharan; Muhammad Bilal Tariq; James C Grotta; Alexandra L Czap Journal: Curr Neurol Neurosci Rep Date: 2022-02-07 Impact factor: 5.081
Authors: Nathaniel R Ellens; Derrek Schartz; Redi Rahmani; Sajal Medha K Akkipeddi; Adam G Kelly; Curtis G Benesch; Stephanie A Parker; Jason L Burgett; Diana Proper; Webster H Pilcher; Thomas K Mattingly; James C Grotta; Tarun Bhalla; Matthew T Bender Journal: Front Neurol Date: 2022-05-09 Impact factor: 4.086
Authors: Verónica V Olavarría; Lorena Hoffmeister; Carolina Vidal; Alejandro M Brunser; Arnold Hoppe; Pablo M Lavados Journal: Front Neurol Date: 2022-04-08 Impact factor: 4.086
Authors: Matthew M Yuen; Anjali M Prabhat; Mercy H Mazurek; Isha R Chavva; Anna Crawford; Bradley A Cahn; Rachel Beekman; Jennifer A Kim; Kevin T Gobeske; Nils H Petersen; Guido J Falcone; Emily J Gilmore; David Y Hwang; Adam S Jasne; Hardik Amin; Richa Sharma; Charles Matouk; Adrienne Ward; Joseph Schindler; Lauren Sansing; Adam de Havenon; Ani Aydin; Charles Wira; Gordon Sze; Matthew S Rosen; W Taylor Kimberly; Kevin N Sheth Journal: Sci Adv Date: 2022-04-20 Impact factor: 14.957
Authors: Andrew Bivard; Henry Zhao; Skye Coote; Bruce Campbell; Leonid Churilov; Nawaf Yassi; Bernard Yan; Michael Valente; Angelos Sharobeam; Anna Balabanski; Angela Dos Santos; Felix Ng; Francesca Langenberg; Michael Stephenson; Karen Smith; Steve Bernard; Vincent Thijs; Geoffrey Cloud; Philip Choi; Henry Ma; Tissa Wijeratne; Chushuang Chen; Liudmyla Olenko; Stephen M Davis; Geoffrey A Donnan; Mark Parsons Journal: BMJ Open Date: 2022-04-29 Impact factor: 3.006